Concepts (151)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Communication | 12 | 2025 | 554 | 3.660 |
Why?
|
| Patient Satisfaction | 3 | 2019 | 410 | 1.480 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 5 | 2021 | 566 | 1.380 |
Why?
|
| Physicians | 3 | 2025 | 436 | 1.290 |
Why?
|
| Physician-Patient Relations | 4 | 2025 | 388 | 1.240 |
Why?
|
| Patient-Centered Care | 4 | 2019 | 249 | 1.200 |
Why?
|
| Hospitals | 4 | 2020 | 376 | 1.200 |
Why?
|
| Patients | 2 | 2020 | 102 | 1.150 |
Why?
|
| Qualitative Research | 4 | 2025 | 612 | 1.100 |
Why?
|
| Decision Making | 3 | 2025 | 390 | 1.050 |
Why?
|
| Quality of Health Care | 3 | 2019 | 519 | 1.000 |
Why?
|
| Health Care Surveys | 3 | 2019 | 279 | 0.830 |
Why?
|
| Focus Groups | 1 | 2024 | 292 | 0.830 |
Why?
|
| Influenza Vaccines | 1 | 2023 | 88 | 0.790 |
Why?
|
| Early Detection of Cancer | 1 | 2025 | 265 | 0.790 |
Why?
|
| Primary Health Care | 2 | 2024 | 647 | 0.770 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 442 | 0.740 |
Why?
|
| Patient Participation | 2 | 2024 | 211 | 0.730 |
Why?
|
| Male | 23 | 2025 | 27578 | 0.710 |
Why?
|
| Vaccination | 4 | 2024 | 337 | 0.710 |
Why?
|
| Delivery of Health Care | 3 | 2019 | 421 | 0.700 |
Why?
|
| Healthcare Disparities | 1 | 2024 | 330 | 0.700 |
Why?
|
| Self-Management | 1 | 2021 | 62 | 0.690 |
Why?
|
| Vaccines | 1 | 2021 | 97 | 0.690 |
Why?
|
| Vaccination Coverage | 1 | 2019 | 6 | 0.670 |
Why?
|
| Noninvasive Ventilation | 2 | 2017 | 70 | 0.670 |
Why?
|
| Humans | 34 | 2025 | 59526 | 0.660 |
Why?
|
| Attitude of Health Personnel | 2 | 2024 | 559 | 0.660 |
Why?
|
| Adult | 12 | 2025 | 15791 | 0.650 |
Why?
|
| Lung Neoplasms | 1 | 2025 | 552 | 0.640 |
Why?
|
| Patient Care | 1 | 2019 | 78 | 0.640 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2024 | 741 | 0.630 |
Why?
|
| Patient Comfort | 1 | 2018 | 2 | 0.630 |
Why?
|
| Continuity of Patient Care | 2 | 2017 | 172 | 0.630 |
Why?
|
| Aged | 17 | 2025 | 13346 | 0.620 |
Why?
|
| Female | 22 | 2025 | 30924 | 0.610 |
Why?
|
| Attitude to Health | 1 | 2020 | 275 | 0.610 |
Why?
|
| Middle Aged | 14 | 2025 | 16279 | 0.600 |
Why?
|
| Medical Errors | 2 | 2017 | 193 | 0.570 |
Why?
|
| Comprehension | 1 | 2018 | 128 | 0.560 |
Why?
|
| Professional-Family Relations | 1 | 2016 | 87 | 0.490 |
Why?
|
| Massachusetts | 7 | 2024 | 2089 | 0.470 |
Why?
|
| Hospital Mortality | 3 | 2017 | 846 | 0.470 |
Why?
|
| Length of Stay | 2 | 2017 | 771 | 0.460 |
Why?
|
| Trust | 2 | 2024 | 68 | 0.440 |
Why?
|
| Surveys and Questionnaires | 4 | 2025 | 2592 | 0.420 |
Why?
|
| Critical Illness | 1 | 2016 | 332 | 0.400 |
Why?
|
| Inpatients | 1 | 2015 | 296 | 0.390 |
Why?
|
| Cross-Sectional Studies | 5 | 2024 | 2470 | 0.390 |
Why?
|
| United States | 9 | 2024 | 7514 | 0.360 |
Why?
|
| Heart Failure | 3 | 2015 | 867 | 0.360 |
Why?
|
| Interviews as Topic | 3 | 2017 | 486 | 0.360 |
Why?
|
| Patient Safety | 3 | 2018 | 243 | 0.350 |
Why?
|
| Activities of Daily Living | 2 | 2021 | 298 | 0.310 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2020 | 119 | 0.290 |
Why?
|
| Neoplasms | 1 | 2017 | 1243 | 0.280 |
Why?
|
| Sarcoidosis, Pulmonary | 1 | 2006 | 12 | 0.280 |
Why?
|
| Epoprostenol | 1 | 2006 | 13 | 0.270 |
Why?
|
| Retrospective Studies | 6 | 2020 | 6011 | 0.260 |
Why?
|
| Acute Disease | 3 | 2017 | 659 | 0.260 |
Why?
|
| Hypertension, Pulmonary | 1 | 2006 | 78 | 0.250 |
Why?
|
| Blood Vessels | 1 | 2006 | 61 | 0.250 |
Why?
|
| Young Adult | 3 | 2024 | 4332 | 0.250 |
Why?
|
| Antihypertensive Agents | 1 | 2006 | 172 | 0.240 |
Why?
|
| Longitudinal Studies | 3 | 2023 | 1225 | 0.240 |
Why?
|
| Hospitalization | 4 | 2021 | 1283 | 0.240 |
Why?
|
| Stem Cells | 1 | 2006 | 257 | 0.220 |
Why?
|
| Physicians, Primary Care | 1 | 2024 | 72 | 0.220 |
Why?
|
| Quality Improvement | 2 | 2019 | 425 | 0.210 |
Why?
|
| Knowledge | 1 | 2022 | 30 | 0.200 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 5092 | 0.200 |
Why?
|
| Intention | 1 | 2022 | 66 | 0.200 |
Why?
|
| Disease Progression | 4 | 2019 | 1044 | 0.190 |
Why?
|
| Patient Discharge | 2 | 2017 | 479 | 0.190 |
Why?
|
| Lung | 1 | 2006 | 833 | 0.180 |
Why?
|
| Intensive Care Units | 2 | 2016 | 449 | 0.170 |
Why?
|
| Mass Screening | 1 | 2025 | 647 | 0.170 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2019 | 33 | 0.160 |
Why?
|
| District of Columbia | 1 | 2018 | 11 | 0.160 |
Why?
|
| Reminder Systems | 1 | 2019 | 72 | 0.160 |
Why?
|
| Maryland | 1 | 2018 | 32 | 0.160 |
Why?
|
| Motivation | 1 | 2021 | 266 | 0.160 |
Why?
|
| Homes for the Aged | 1 | 2020 | 164 | 0.150 |
Why?
|
| Uncertainty | 1 | 2018 | 32 | 0.150 |
Why?
|
| Culture | 1 | 2018 | 76 | 0.150 |
Why?
|
| Health Education | 1 | 2019 | 184 | 0.150 |
Why?
|
| Cooperative Behavior | 1 | 2019 | 220 | 0.150 |
Why?
|
| Inventories, Hospital | 1 | 2017 | 3 | 0.150 |
Why?
|
| Calcitonin | 1 | 2017 | 17 | 0.150 |
Why?
|
| Patient Preference | 1 | 2018 | 76 | 0.150 |
Why?
|
| Nursing Homes | 2 | 2021 | 665 | 0.150 |
Why?
|
| Hospitals, Low-Volume | 1 | 2017 | 21 | 0.140 |
Why?
|
| Hospitals, High-Volume | 1 | 2017 | 36 | 0.140 |
Why?
|
| Medicare | 1 | 2021 | 601 | 0.140 |
Why?
|
| Electronic Health Records | 1 | 2019 | 352 | 0.130 |
Why?
|
| Registries | 1 | 2019 | 803 | 0.130 |
Why?
|
| Survival Rate | 2 | 2015 | 791 | 0.130 |
Why?
|
| Pandemics | 1 | 2020 | 608 | 0.130 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2015 | 39 | 0.120 |
Why?
|
| Homosexuality, Male | 1 | 2015 | 38 | 0.120 |
Why?
|
| Adolescent | 2 | 2024 | 5932 | 0.120 |
Why?
|
| Mother-Child Relations | 1 | 2015 | 46 | 0.120 |
Why?
|
| Patient Care Team | 1 | 2017 | 327 | 0.120 |
Why?
|
| Multiple Myeloma | 1 | 2019 | 323 | 0.120 |
Why?
|
| Algorithms | 1 | 2019 | 990 | 0.110 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 142 | 0.110 |
Why?
|
| Comorbidity | 2 | 2015 | 1091 | 0.110 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2015 | 149 | 0.110 |
Why?
|
| Databases, Factual | 1 | 2017 | 838 | 0.110 |
Why?
|
| Outpatients | 1 | 2015 | 131 | 0.110 |
Why?
|
| Treatment Outcome | 3 | 2017 | 5183 | 0.110 |
Why?
|
| Stroke Volume | 1 | 2014 | 318 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 724 | 0.100 |
Why?
|
| Mortality | 1 | 2012 | 159 | 0.090 |
Why?
|
| Data Collection | 1 | 2012 | 384 | 0.090 |
Why?
|
| HIV Infections | 1 | 2015 | 921 | 0.080 |
Why?
|
| Telemedicine | 1 | 2012 | 335 | 0.070 |
Why?
|
| Vascular Resistance | 1 | 2006 | 44 | 0.070 |
Why?
|
| Infusions, Intravenous | 1 | 2006 | 170 | 0.070 |
Why?
|
| Pulmonary Veins | 1 | 2006 | 35 | 0.060 |
Why?
|
| Myocardial Infarction | 1 | 2012 | 864 | 0.060 |
Why?
|
| Pulmonary Artery | 1 | 2006 | 90 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 809 | 0.060 |
Why?
|
| Cluster Analysis | 1 | 2024 | 250 | 0.060 |
Why?
|
| Blood Pressure | 1 | 2006 | 522 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2021 | 3101 | 0.050 |
Why?
|
| Mobile Applications | 1 | 2024 | 130 | 0.050 |
Why?
|
| Risk Factors | 3 | 2020 | 5017 | 0.050 |
Why?
|
| Logistic Models | 2 | 2015 | 1252 | 0.040 |
Why?
|
| Polypharmacy | 1 | 2020 | 62 | 0.040 |
Why?
|
| Long-Term Care | 1 | 2020 | 174 | 0.040 |
Why?
|
| Prognosis | 2 | 2014 | 1572 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2020 | 1063 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 1032 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 422 | 0.030 |
Why?
|
| Unsafe Sex | 1 | 2015 | 27 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 926 | 0.030 |
Why?
|
| Risk-Taking | 1 | 2015 | 160 | 0.030 |
Why?
|
| Cause of Death | 1 | 2014 | 200 | 0.030 |
Why?
|
| Biomarkers | 1 | 2017 | 1211 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2017 | 420 | 0.030 |
Why?
|
| Renal Insufficiency | 1 | 2012 | 62 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2012 | 553 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 1915 | 0.020 |
Why?
|
| Sex Factors | 1 | 2012 | 960 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 2329 | 0.020 |
Why?
|
| Age Factors | 1 | 2012 | 1518 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 703 | 0.020 |
Why?
|
| Animals | 1 | 2006 | 19663 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 1551 | 0.020 |
Why?
|
| Time Factors | 1 | 2014 | 3579 | 0.020 |
Why?
|